Evidence map›Paper›PMID 33558279›Full record

ArticleJournal for immunotherapy of cancer2021

Short-term response to immune-chemotherapy and immune features of a ceritinib-resistant patient with

Dongsheng Yue, Juanjuan Qian, Zhipeng Chen, Bin Zhang, Peng Chen, Lei Zhang, Jingjing Li, Henghui Zhang, Changli Wang

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Dongsheng Yue *Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Juanjuan Qian *Genecast Biotechnology Co., Ltd, Wuxi, China.
Zhipeng Chen *Key Laboratory of Functional Protein Research of Guangdong, Higher Education Institutes and MOE Key Laboratory of Tumor Molecular Biology, Institute of Life and Health Engineering, Jinan University, Guangzhou, China.
Bin ZhangDepartment of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Peng ChenGenecast Biotechnology Co., Ltd, Wuxi, China.
Lei ZhangGenecast Biotechnology Co., Ltd, Wuxi, China.
Jingjing LiDepartment of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Henghui ZhangInstitute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China wangchangli@tjmuch.com zhhbao@ccmu.edu.cn.
Changli WangDepartment of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China wangchangli@tjmuch.com zhhbao@ccmu.edu.cn.
Tianjin Medical University Cancer Institute and Hospital · CNGenecast (China) · CNCapital Medical University · CNJinan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with

Indexed as

Gene RearrangementAdenocarcinoma of LungAdultAminopyridinesAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorDrug Resistance, NeoplasmHumansImmune Checkpoint InhibitorsLactamsLung NeoplasmsMaleMutationNeoplasm StagingNivolumabProtein Kinase InhibitorsAminopyridinesBiomarkers, TumorceritinibImmune Checkpoint InhibitorsLactamslorlatinibNivolumabProtein Kinase InhibitorsProtein-Tyrosine KinasesProto-Oncogene ProteinsPyrazolesPyrimidinesROS1 protein, humanSulfonesbiomarkerscase reportsimmunotherapylung neoplasmstumortumor microenvironment

Identifiers

PMID33558279
PMCPMC7871696
OpenAlexW3126873660

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.